GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Chembio Diagnostics Inc (NAS:CEMI) » Definitions » WACC %

Chembio Diagnostics (Chembio Diagnostics) WACC % :10.76% (As of May. 06, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Chembio Diagnostics WACC %?

As of today (2024-05-06), Chembio Diagnostics's weighted average cost of capital is 10.76%%. Chembio Diagnostics's ROIC % is -67.63% (calculated using TTM income statement data). Chembio Diagnostics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


Chembio Diagnostics WACC % Historical Data

The historical data trend for Chembio Diagnostics's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chembio Diagnostics WACC % Chart

Chembio Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.46 11.69 13.70 11.34 11.76

Chembio Diagnostics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.34 11.33 12.13 12.34 11.76

Competitive Comparison of Chembio Diagnostics's WACC %

For the Diagnostics & Research subindustry, Chembio Diagnostics's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chembio Diagnostics's WACC % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Chembio Diagnostics's WACC % distribution charts can be found below:

* The bar in red indicates where Chembio Diagnostics's WACC % falls into.



Chembio Diagnostics WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Chembio Diagnostics's market capitalization (E) is $16.710 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2022, Chembio Diagnostics's latest one-year quarterly average Book Value of Debt (D) is $25.7166 Mil.
a) weight of equity = E / (E + D) = 16.710 / (16.710 + 25.7166) = 0.3939
b) weight of debt = D / (E + D) = 25.7166 / (16.710 + 25.7166) = 0.6061

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.481%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Chembio Diagnostics's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.481% + 1 * 6% = 10.481%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Dec. 2022, Chembio Diagnostics's interest expense (positive number) was $2.813 Mil. Its total Book Value of Debt (D) is $25.7166 Mil.
Cost of Debt = 2.813 / 25.7166 = 10.9385%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0.034 / -23.256 = -0.15%, which is less than 0%. Therefore it's set to 0%.

Chembio Diagnostics's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.3939*10.481%+0.6061*10.9385%*(1 - 0%)
=10.76%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chembio Diagnostics  (NAS:CEMI) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Chembio Diagnostics's weighted average cost of capital is 10.76%%. Chembio Diagnostics's ROIC % is -67.63% (calculated using TTM income statement data). Chembio Diagnostics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Chembio Diagnostics (Chembio Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
3661 Horseblock Road, Medford, NY, USA, 11763
Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.
Executives
Perceptive Credit Advisors, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Leslie Teso-lichtman director C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Charles Caso officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Paul Angelico officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Lawrence J. Steenvoorden officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
David William Bespalko director 29 CEDAR DRIVE, ALLENDALE NJ 07401
David Acheson director C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Richard Eberly officer: See Remarks 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John Gary Potthoff director 6140 SPANISH OAKS CLUB BLVD., AUSTIN TX 78738
Javan Esfandiari officer: Senior Vice President 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Robert Passas officer: See Remarks 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Polan Mary Lake Ph D director STANFORD UNIVERSITY SCHOOL OF MEDICINE, 300 PASTAUR DR ROOM HH333, STANFORD CA 94305-5317
Neil A Goldman officer: Executive VP and CFO 3661 HORSEBLOCK RD, MEDFORD NY 11763

Chembio Diagnostics (Chembio Diagnostics) Headlines

From GuruFocus

Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement

By Stock market mentor Stock market mentor 01-31-2023

Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

By sperokesalga sperokesalga 04-27-2023